SCHEDULE 14A
SCHEDULE 14A INFORMATION
PROXY STATEMENT PURSUANT TO SECTION 14(A)
OF THE SECURITIES EXCHANGE ACT OF 1934
Filed by the Registrant [ ]
Filed by a Party other than the Registrant [X]
Check the appropriate box:
[ ] Preliminary Proxy Statement
[ ] Confidential, For Use of the Commission Only (as permitted by
Rule 14a-6(e)(2))
[ ] Definitive Proxy Statement
[ ] Definitive Additional Materials
[X] Soliciting Material Pursuant to Section 240.14a-12
SYNAPTIC PHARMACEUTICAL CORPORATION
-----------------------
(Name of Registrant as Specified in its Charter)
-----------------------
H. LUNDBECK A/S
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
Payment of Filing Fee (Check the appropriate box):
[X] No fee required.
[ ] Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
(1) Title of each class of securities to which transaction applies:
(2) Aggregate number of securities to which transaction applies:
(3) Per unit price or other underlying value of transaction computed
pursuant to Exchange Act Rule 0-11 (set forth the amount on which
the filing fee is calculated and state how it was determined):
(4) Proposed maximum aggregate value of transactions:
(5) Total fee paid:
----------
[ ] Fee paid previously with preliminary materials.
[ ] Check box if any part of the fee is offset as provided by Exchange Act
Rule 0-11(a)(2) and identify the filing for which the offsetting fee was
paid previously. Identify the previous filing by registration statement
number, or the Form or Schedule and the date of its filing.
(1) Amount Previously Paid:
(2) Form, Schedule or Registration Statement No.:
(3) Filing Party:
(4) Date Filed:
2
Set forth as Exhibit 99.1 is a transcript of the Synaptic acquisition
teleconference held by H. Lundbeck A/S on November 21, 2002.
Please note that the merger described in the teleconference is contingent on
approval by the Synaptic stockholders, regulatory approvals and other
customary closing conditions, including obtaining Hart-Scott-Rodino approval.
Synaptic is a pioneer in the development of pharmaceuticals that target G
protein-coupled receptors (GPCRs) to achieve superior efficacy and safety in
the treatment of disorders such as depression, diabetes, obesity, pain and
incontinence. As of November 21, 2002, Synaptic is collaborating with
Grunenthal GmbH on discovering compounds for the alleviation of pain and with
Kissei Pharmaceutical Co., Ltd. to identify novel G protein- coupled receptors
that can provide new drug discovery targets for Kissei. Glaxo Group Limited,
Eli Lilly and Company, Novartis Pharma A.G. and Ranbaxy Laboratories Limited
have also been granted licenses by Synaptic.
H. Lundbeck A/S is an international pharmaceutical company engaged in the
research and development, production, marketing and sale of drugs for the
treatment of psychiatric and neurological disorders. In 2001, the Company's
revenue was DKK 7.7 billion. The number of employees is approx. 4,800.
ADVISORS
Lundbeck was advised by JPMorgan. Synaptic was advised by Bank of
America Securities.
FORWARD LOOKING STATEMENTS
The forward-looking statements contained in this announcement are based on the
management's current expectations concerning certain future events and
results. These are, of course, subject to uncertainty, and actual results may
therefore differ materially from those expressed by the statements. Further,
some of the expectations are based upon assumptions about future events, which
may turn out to be incorrect.
ADDITIONAL INFORMATION
Stockholders of Synaptic are urged to read the proxy statement that Synaptic
will file on Schedule 14A with the Securities and Exchange Commission ("SEC")
when it becomes available, and any other relevant documents filed or to be
filed in the future with the SEC because those documents contain important
information about Synaptic, the proposed transactions and related matters.
Investors and security holders can obtain free copies of the proxy statement
at Synaptic's web site, www.synapticcorp.com or by contacting Investor
Relations, Synaptic Pharmaceutical Corporation, 215 College Road, Paramus, NJ
07652 (Telephone: (201) 261-1331, ext. 1410). Investors and security holders
can also obtain free copies of the proxy statement and other documents filed
by Synaptic and henceforth by Lundbeck with the SEC in connection with the
proposed transactions at the SEC's web site at www.sec.gov.
In addition to the proxy statement, Synaptic files annual, quarterly and
special reports, proxy statements and other information with the SEC, each of
which are available at the SEC's web site at www.sec.gov. Lundbeck has not
previously filed any reports or other information with the SEC because
Lundbeck has no securities registered pursuant to the Securities Exchange Act
of 1934, as amended. You may also read and copy any reports, statements and
other information filed by Synaptic and henceforth by Lundbeck at the
3
SEC public reference room at 450 Fifth Street, N.W., Washington, D.C. 20549.
Please call the SEC at 1-800-SEC-0330 for further information.
Synaptic, Lundbeck, and their respective directors, executive officers and
certain members of management and other employees may be deemed to be
participants in the solicitation of proxies of Synaptic's stockholders to
approve the proposed transactions. Such individuals may have interests in the
transactions, including as a result of holding options or shares of Synaptic's
stock. Information regarding Lundbeck and its directors and officers is
contained in its DFAN 14A, filed with the SEC on November 21, 2002.
Information regarding Synaptic and its directors and officers is contained in
its proxy statement on Schedule 14A, filed with the SEC on April 8, 2002.
INFORMATION REGARDING PARTICIPANTS ON BEHALF OF LUNDBECK
Set forth below is the name, business address, principal occupation or
employment and citizenship of each director and executive officer of Lundbeck.
The name of each person who is a director of Lundbeck is marked with an
asterisk. The business address of each person listed below is 9 Ottiliavej,
DK-2500 Valby, Copenhagen, Denmark. As of the date of this filing, none of the
directors or executive officers listed below individually held any options or
shares of Synaptic securities.
Name and Business Address Principal Occupation or Employment Citizenship
-------------------------------------------- -------------------------------------------------- -----------------------
ERIK SPRUNK-JANSEN President and Chief Executive Officer of Lundbeck Denmark
-------------------------------------------- -------------------------------------------------- -----------------------
CLAUS BRAESTRUP Executive Vice President, Research and Denmark
Development of Lundbeck
-------------------------------------------- -------------------------------------------------- -----------------------
LARS BANG Senior Vice President, Commercial Operations, Denmark
Europe and Overseas of Lundbeck
-------------------------------------------- -------------------------------------------------- -----------------------
HARALD CONRADI-LARSEN Senior Vice President, Human Resource Norway
Management of Lundbeck
-------------------------------------------- -------------------------------------------------- -----------------------
Senior Vice President, Corporate Affairs and
STIG LOKKE PEDERSEN Commercial Operations, America and Asia of Denmark
Lundbeck
-------------------------------------------- -------------------------------------------------- -----------------------
HANS HENRIK MUNCH-JENSEN Senior Vice President, Corporate Finance and Denmark
Communication of Lundbeck
-------------------------------------------- -------------------------------------------------- -----------------------
OLE MOESTRUP Senior Vice President, Strategic Marketing of Denmark
Lundbeck
-------------------------------------------- -------------------------------------------------- -----------------------
MORTEN KOLD MIKKELSEN Senior Vice President, Supply Operations and Denmark
Engineering of Lundbeck
-------------------------------------------- -------------------------------------------------- -----------------------
ARNE V. JENSEN* Chairman Denmark
-------------------------------------------- -------------------------------------------------- -----------------------
OLE STEEN ANDERSEN Executive Vice President, Chief Financial Officer ofDenmark
Danfoss
-------------------------------------------- -------------------------------------------------- -----------------------
LARS BRUHN* President and Chief Executive Officer of Bruhn Denmark
Group
-------------------------------------------- -------------------------------------------------- -----------------------
PETER KURSTEIN* Executive Vice President of Radiometer Medical Denmark
-------------------------------------------- -------------------------------------------------- -----------------------
SVEN DYRLOV MADSEN* Director Denmark
-------------------------------------------- -------------------------------------------------- -----------------------
4
-------------------------------------------- -------------------------------------------------- -----------------------
OLE VAHLGREN* Vice President, U.S. Operations of Lundbeck, Inc. Denmark
-------------------------------------------- -------------------------------------------------- -----------------------
FLEMMING LINDELOV* Chief Executive Officer of Royal Scandinavia Denmark
-------------------------------------------- -------------------------------------------------- -----------------------
JAN GOTTLIEBSEN* Teamleader Liquid & Sterile Production of Lundbeck Denmark
-------------------------------------------- -------------------------------------------------- -----------------------
BIRGIT BUNDGAARD ROSENMEIER* Head of Department, Quality Sterile Production of Denmark
Lundbeck
-------------------------------------------- -------------------------------------------------- -----------------------
TORBEN SKARSFELDT* Head of Department, Corporate Licensing of Denmark
Lundbeck
-------------------------------------------- -------------------------------------------------- -----------------------
4
INDEX TO EXHIBITS
Exhibit No. Exhibit
----------- -------
99.1 Transcript of the Synaptic Acquisition Teleconference held
by H. Lundbeck A/S on November 21, 2002